Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 studyПодробнее

Capivasertib Approved to Treat Patients with Advanced (HR+/HER2-) Breast Cancer │ PharmacologyПодробнее

Breast Cancer Clinical Trials: An Inside Look at ImmunotherapyПодробнее

Evolution of HER2-Targeted Therapy in Biliary Tract CancerПодробнее

Dr. Rimawi on the Clinical Need for Immunotherapy in HER2-Positive Breast CancerПодробнее

Immunotherapy Combination in HER2-Positive Breast CancerПодробнее

HR+ HER2- Breast Cancer Clinical TrialПодробнее

Dr Davis on the Investigation of Neratinib + Trastuzumab Deruxtecan in Advanced HER2+ Solid TumorsПодробнее

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast CancerПодробнее

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast CancerПодробнее

Clinical Trials and Breast Cancer | Benefits to the PatientПодробнее

Combining Anti-HER2 Agents With Immunotherapy for HER2+ mBCПодробнее

Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancerПодробнее

Future role of immunotherapy in HER2+ breast cancerПодробнее

Key challenge associated with the management of HR+/HER2- breast cancerПодробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее

HER2 Positive Breast Cancer: Everything You Must KnowПодробнее

Immunotherapy, CHARIOT and DIAmOND Clinical Trials - Breast Cancer Trials PodcastПодробнее

Study of Immunotherapy Combinations for Patients with HER2-Positive Metastatic Breast CancerПодробнее